La desregulaci\u00f3 dels nivells d’ARN i prote\u00efnes, en comparaci\u00f3 amb els dels teixits normals, \u00e9s una caracter\u00edstica molecular constant de tots els c\u00e0ncers. Darrere de les causes d\u2019aquests canvis, recentment s\u2019han identificat modificacions qu\u00edmiques a les mol\u00e8cules d\u2019ARN que afectarien a la seva estabilitat, ubicaci\u00f3 o capacitat de produir prote\u00efnes.<\/p>\n
Aquest \u00e9s el cas del limfoma de Hodgkin, que constitueix aproximadament un 25-30% de tots els limfomes i que gr\u00e0cies als constants aven\u00e7os cient\u00edfics \u00e9s curable en un 85% dels casos amb el tractament de primera l\u00ednea. Malauradament, encara hi un 15% de pacients que segueixen sense respondre a la ter\u00e0pia<\/strong> i tenen una superviv\u00e8ncia molt redu\u00efda.<\/p>\n Ara, en un article publicat a la revista Blood<\/a> liderat per l’Institut de Recerca contra la Leuc\u00e8mia Josep Carreras (IJC) i amb la participaci\u00f3 de cient\u00edfics de l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO) i l\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), es senyala un biomarcador que permetria identificar els casos que acabaran desenvolupant una malaltia m\u00e9s agressiva i per tant requereixen una atenci\u00f3 especial.<\/p>\n \u201cHem trobat que ALKBH3 \u00e9s capa\u00e7 de regular l\u2019activitat de l\u2019ARN, el pas entremig entre el genoma i les prote\u00efnes\u201d, explica la Dra. Anna Sureda<\/strong>, del Grup de Tumors del Sistema Hematopo\u00e8tic i Limfoides<\/a> de l\u2019IDIBELL i Cap del Servei d\u2019Hematologia Cl\u00ednica de l\u2019ICO. A m\u00e9s, els resultats indiquen que aquesta activitat reguladora \u00e9s especialment important en el limfoma de Hodgkin. \u201cLes c\u00e8l\u00b7lules canceroses d\u2019aquest tipus de tumor no expressen el gen ALKBH3, el que estaria provocant que tinguessin m\u00e9s capacitat de proliferar i per tant fossin m\u00e9s malignes\u201d, explica Sureda.<\/p>\n Aquest descobriment, obre la porta a desenvolupar tractaments espec\u00edfics per aquests pacients a trav\u00e9s de la substituci\u00f3 de l\u2019activitat de ALKBH3 o la reactivaci\u00f3 de la seva expressi\u00f3. \u201cSense ALKBH3 les c\u00e8l\u00b7lules canceroses poden modificar el microambient que les envolta i eliminar les barreres pel seu creixement. Per aix\u00f2 \u00e9s molt important el desenvolupament de bons models tumorals, a partir dels limfomes amb aquesta alteraci\u00f3, on poder avaluar noves estrat\u00e8gies terap\u00e8utiques\u201d, conclou el Dr. Alberto Villanueva<\/strong>, cap del Grup de Resist\u00e8ncia Farmacol\u00f2gica i Xenografts<\/a> del programa ProCURE de l\u2019IDIBELL i l\u2019ICO i col\u00b7laborador d\u2019aquest estudi.<\/p>\n","protected":false},"excerpt":{"rendered":" L\u2019abs\u00e8ncia d\u2019ALKBH3 permet a les c\u00e8l\u00b7lules canceroses cr\u00e9ixer amb m\u00e9s llibertat i \u00e9s un indicador de malignitat per aquest tipus de tumors. L\u2019estudi, publicat a Blood, compta amb la participaci\u00f3 de l’IDIBELL, l\u2019ICO-Hospitalet i el HUB, entre d\u2019altres.<\/p>\n","protected":false},"author":8,"featured_media":14880,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1,332,346,449],"tags":[],"class_list":["post-14879","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar","category-cancer","category-quimioresistencia-tumoral-i-estromal","category-tumors-hematopoetics-i-limfoides"],"publishpress_future_action":{"enabled":false,"date":"2025-03-02 07:33:29","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/14879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=14879"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/14879\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/14880"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=14879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=14879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=14879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}